| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
/
T Cell Lymphomas Are Derived from Different V
Subsets of
/
T Lymphocytes









From the Institute of Human Genetics,
*
Poznan, Poland; the University of Pennsylvania,
Philadelphia, Pennsylvania; Vanderbilt University,
Nashville, Tennessee; the Johns Hopkins University,
Baltimore, Maryland; the University of Pittsburgh,
¶
Pittsburgh, Pennsylvania; and Harvard University,
||
Boston, Massachusetts
Gamma/delta T cell lymphomas (
/
TCL) represent rare,
often aggressive types of T cell malignancy that are clinically and
pathologically diverse. Most
/
TCL occur as a hepatosplenic or
subcutaneous type. To date, analysis of the T cell receptor
(TCR
) gene repertoire of hepatosplenic
/
TCL (
/
HSTCL)
and subcutaneous panniculitis-like
/
TCL (
/
SPTCL) has been
reported only in a limited number of cases. In this study we analyzed
11
/
HSTCL and 4
/
SPTCL by polymerase chain reaction and
immunostaining to determine their usage of the V
subtypes
(V
16). It is noteworthy that 10 of 11
/
HSTCL expressed the
V
1 gene. The remaining case also expressed T cell receptor
(TCR
) as determined by flow cytometry and TCR
rearrangement in
Southern blot. However, the V
gene expressed by this
lymphoma could not be determined, which suggests usage of an as
yet unidentified V
gene. In striking contrast to the
/
HSTCL, all 4
/
SPTCL expressed the V
2 gene. Our data
demonstrate that
/
HSTCL are preferentially derived from the
V
1 subset of
/
T lymphocytes, whereas
/
SPTCL
are preferentially derived from the V
2 subset. The pattern of V
gene expression in HSTCL and SPTCL corresponds to the
respective, predominant
/
T cell subsets normally found
in the spleen and skin. This finding suggests that
/
TCL are
derived from normal
/
T lymphocytes which reside in the affected
tissues. Furthermore, the selective, lymphoma
type-specific V
gene segment usage may provide a molecular tool to
distinguish better among various types of
/
TCL lymphoma
particularly in the clinically advanced, widely disseminated
cases.
This article has been cited by other articles:
![]() |
M. A. Rizvi, A. M. Evens, M. S. Tallman, B. P. Nelson, and S. T. Rosen T-cell non-Hodgkin lymphoma Blood, February 15, 2006; 107(4): 1255 - 1264. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Belhadj, F. Reyes, J.-P. Farcet, H. Tilly, C. Bastard, R. Angonin, E. Deconinck, F. Charlotte, V. Leblond, E. Labouyrie, et al. Hepatosplenic {gamma}{delta} T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients Blood, December 15, 2003; 102(13): 4261 - 4269. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Toro, D. J. Liewehr, N. Pabby, L. Sorbara, M. Raffeld, S. M. Steinberg, and E. S. Jaffe Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma Blood, May 1, 2003; 101(9): 3407 - 3412. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. K. Aronson and V. C. Fiedler Of Mice and Men: The Road to Understanding the Complex Nature of Adipose Tissue and Lipoatrophy Arch Dermatol, January 1, 2003; 139(1): 81 - 83. [Full Text] [PDF] |
||||
![]() |
M. E. Kadin Cutaneous {gamma}{delta} T-Cell Lymphomas--How and Why Should They Be Recognized? Arch Dermatol, August 1, 2000; 136(8): 1052 - 1054. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |